Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

BACKGROUND: Antiangiogenic agents have improved the prognosis of non-squamous non-small–cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor’s characteristics or comorbidities. Much less information is available a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Manag Res
Hlavní autoři: Vergnenègre, Alain, Basse, Victor, Le Garff, Gwenaelle, Bylicki, Olivier, Dubos-Arvis, Catherine, Comet, Bénédicte, Marcq, Marie, Le Treut, Jacques, Auliac, Jean-Bernard, Madroszyk, Anne, Fraboulet, Gislaine, Crequit, Jacky, Thomas, Pascal, Paleiron, Nicolas, Monnet, Isabelle
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938186/
https://ncbi.nlm.nih.gov/pubmed/31920391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S219984
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky